Data Year:

For its 2025 fiscal year, JANUX THERAPEUTICS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
David Campbell Ph.D.
President and Chief Executive Officer
Total Compensation $13,506,231 View details Pay Rank By Title In Biotechnology industry #70 View more
Byron Robinson Ph.D., J.D.
Former Chief Strategy Officer
Total Compensation $5,063,635 View details Pay Rank By Title In Biotechnology industry #27 View more
Thomas DiRaimondo Ph.D.
Chief Scientific Officer
Total Compensation $4,345,469 View details Pay Rank By Title In Biotechnology industry #11 View more
Zachariah McIver D.O., Ph.D.
Former Chief Medical Officer
Total Compensation $4,639,495 View details Pay Rank By Title In Biotechnology industry #35 View more
Janeen Doyle
Chief Corporate and Business Development Officer
Total Compensation $4,669,292 View details Pay Rank By Title In Biotechnology industry #1 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at JANUX THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. JANUX THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. JANUX THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
David Campbell Ph.D.
President and Chief Executive Officer
Total Cash $1,047,200 Equity $12,459,031 Other $0 $13,506,231
Byron Robinson Ph.D., J.D.
Former Chief Strategy Officer
Total Cash $362,728 Equity $4,306,826 Other $394,081 $5,063,635
Thomas DiRaimondo Ph.D.
Chief Scientific Officer
Total Cash $653,904 Equity $3,691,565 Other $0 $4,345,469
Zachariah McIver D.O., Ph.D.
Former Chief Medical Officer
Total Cash $640,300 Equity $3,999,195 Other $0 $4,639,495
Janeen Doyle
Chief Corporate and Business Development Officer
Total Cash $499,029 Equity $4,120,263 Other $50,000 $4,669,292
For its 2025 fiscal year, JANUX THERAPEUTICS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
David Campbell Ph.D. CEO Pay $13,506,231 Median Employee Pay $455,932 CEO Pay Ratio 30:1
For its 2024 fiscal year, JANUX THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alana McNulty Total Cash $391,532
Eric Dobmeier Total Cash $997,406
Jake Simson, Ph.D. Total Cash $398,532
Jay Lichter, Ph.D. Total Cash $385,404
Natasha Hernday Total Cash $997,406
Ron Barrett, Ph.D. Total Cash $416,070
Sheila Gujrathi Total Cash $384,032
Vickie Capps Total Cash $399,032
Winston Kung Total Cash $391,532
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.